Skip to main content
Premium Trial:

Request an Annual Quote

Roche Signs Epigenomics for Cancer Diagnostic, Prognostic Collaboration

NEW YORK, March 18 - Roche and Epigenomics announced today a three-year collaboration to develop molecular diagnostic and pharmacagenomic assays for cancer that use Epigenomics' DNA methylation technologies.

 

Under the agreement, Roche will pay Epigenomics, of Seattle, Euro 4 million ($4.25 million), as well as R&D funding, milestone payments, and royalties on sales of products, that could total up to Euro 100 Million ($106.3 million).

 

The products to be developed include diagnostic and prognostic tools for colon, breast, and prostate cancer, as well as pharmacagenomics tests to predict response to anti-cancer drugs, the companies said. Roche will use its PCR and microarray technology in the assays.

 

The methylation technologies involve measuring the differences in DNA methylation between diseased and healthy conditions. Methylation, the phenomenon wherein a methyl group is attached to the cytosine base on DNA, is a major mechanism of control for gene expression.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.